Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL Treatment Of NK Cells More Than Doubles Ability To Kill Tumor Cells
Portfolio Pulse from Happy Mohamed
Phio Pharmaceuticals announced pre-clinical data showing that its INTASYL RNAi platform technology can more than double the ability of NK cells to kill tumor cells. The treatment silences TIGIT and CBL-B, improving the anti-tumor response of NK cells and creating a more effective cell therapy for cancer treatment.
May 18, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals' pre-clinical data shows that its INTASYL RNAi platform technology can significantly improve the anti-tumor response of NK cells, potentially leading to a more effective cancer treatment.
The pre-clinical data demonstrates the potential of Phio Pharmaceuticals' INTASYL RNAi platform technology to improve the anti-tumor response of NK cells, which could lead to a more effective cancer treatment. This positive news may increase investor confidence in the company and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100